Compare iShares Core High Dividend ETF (HDV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs TG Therapeutics Inc — how do they compare? iShares Core High Dividend ETF trades at $28.75 (market cap $14.68B), while TG Therapeutics Inc trades at $54.91 (market cap $8.16B). The key difference: iShares Core High Dividend ETF is the larger of the two by market cap, and iShares Core High Dividend ETF is more actively traded (2,925,562 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and TG Therapeutics Inc for 16 Days on average.
| HDV | TGTX | |
|---|---|---|
Market Cap | $14.68B | $8.16B |
Volume | 2,925,562 | 1,735,121 |
52-Week High | $29.93 | $59.06 |
52-Week Low | $23.64 | $26.94 |
Typical Hold Time | 117 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.72, up 1.56% today with a bullish technical signal supported by moving averages. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities, resulting in heightened concentration risk with nearly 62% allocation to three sectors. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation despite the 3% yield not fully compensating for reduced diversification.
The outlook remains cautiously optimistic given the ETF's strong 2026 performance against the S&P 500, though investors face concentration risks from the recent sector shift. Key opportunities include the fund's competitive 0.08% expense ratio and dividend focus during market rotation, while risks center on sector concentration and whether the current yield adequately compensates for reduced diversification in the portfolio construction.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
